Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Abm Therapeutics Corporation is active in the Biotechnology & Pharmaceuticals technology area, where it currently manages 1 pending office action. This action is assigned to 1 distinct examiner, reflecting a concentrated effort in its patent prosecution. The data shows that the portfolio is also limited to 1 distinct art unit, which suggests that the company's current innovations are focused within a narrow technical niche. This structure allows for a very specific legal strategy tailored to the requirements of that single art unit at the USPTO.
The busiest examiner identified in the data is BARSKY, JARED, who is handling the 1 busiest examiner pending office action. As the only examiner currently engaged with the portfolio, BARSKY, JARED is the central figure in determining the success of the company's pending claims. For the practitioner, this means that understanding this examiner's past decisions and preferences is critical. The fact that there is only 1 distinct examiner simplifies the communication process between the applicant and the USPTO.
Having 1 pending office action means the portfolio is in a relatively quiet but critical phase of its development. Since the 1 distinct examiner is also the busiest examiner, the entire immediate future of the portfolio's growth rests on this single interaction. This concentration allows the company to dedicate its full attention to resolving the issues raised in this one action, potentially leading to a more robust and well-defined patent grant for its therapeutic technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.3% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019377 | KINASE INHIBITORS AND USES THEREOF | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019377 | KINASE INHIBITORS AND USES THEREOF | BARSKY, JARED | 1628 | §102 | Final Rejection | — | Pending | Feb 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbm Therapeutics Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jared Barsky has the most, with 1 of Abm Therapeutics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.